Updated:
COVID-19 HPC Consortium
The COVID-19 High Performance Computing Consortium is a private-public sector collaboration providing computing capabilities for COVID-19 research.
COVID-19 HPC Consortium
The COVID-19 High Performance Computing Consortium is a private-public sector collaboration providing computing capabilities for COVID-19 research. It has made one investment, in Repertoire Immune Medicines, as part of a grant on June 24, 2020.
General information
Firm type
other
Year founded
2020
Location
Region
North America
Country
United States
Corporate office
United States
Principals
Thomas Zacharia
Director, Oak Ridge National Laboratory (lead partner representative)
France Córdova
Director, National Science Foundation (lead partner representative)
Sector focus
Frequently asked questions
Who funded the COVID-19 HPC Consortium?
The consortium did not operate with a dedicated budget. Participating organizations contributed in-kind resources: computing time, technical expertise, and network infrastructure. Primary contributors included the National Science Foundation, the Department of Energy, IBM, and major academic computing centers (per the consortium's official communications, 2020).
What types of research received compute time?
Projects included molecular dynamics simulations of viral proteins, drug docking studies for repurposing existing drugs, and epidemiological modeling of transmission patterns. All proposals were reviewed for scientific merit and relevance to COVID-19 (per the consortium's website).
How long did the consortium operate?
The COVID-19 HPC Consortium was active from March 2020 through late 2021. As the pandemic entered an endemic phase and dedicated public health infrastructure emerged, the formal allocation process wound down (per public record).
Was the consortium a family office or investment vehicle?
No. The COVID-19 HPC Consortium was a research coordination initiative, not an investment entity. It had no AUM, no investment professionals, and no financial mandate. This profile documents it as a notable public-private health data consortium.
What happened to the consortium's computing resources after it ended?
The partner institutions retained their HPC capacity for ongoing research. Some projects spun off into independent research programs at national laboratories. No formal successor entity exists (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: